Azilsartan kamedoxomil: solubility enhancement techniques

Asmaa Abdelaziz Mohamed

College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq

*Corresponding author:

College of Pharmacy, Al-Zahraa University for Women, Karbala, Iraq

E-mail address: asmaa.abdelaziz@alzahraa.edu.iq

Tel: + 9647850485328.

ORCID: https://orcid.org/0000-0002-2609-5226

Azilsartan kamedoxomil: solubility enhancement techniques

Abstract

Azilsartan kamedoxomil (AZ) belongs to biopharmaceutical solubility class IV (BCS IV) that has low solubility and low permeability. Therefore, several techniques should be utilized to enhance its bioavailability, especially solubility enhancement. The most critical step in achieving the AZ desired strength in systemic circulation for anticipated pharmacological action is the dissolution of AZ. The low solubility of new chemicals is a significant obstacle in formulation and generic development. AZ is to be absorbed; it should exist in the soluble state at the site of action. Diverse approaches are employed to improve its solubility, including physicochemical changing of AZ or other techniques like particle size reduction, solid dispersion, and complexation. Improving AZ solubility depends on drug characteristics, absorption site, and dosage requirements. The recent techniques of solubilization and enhancing bioavailability were the focus of this review.

Keywords azilsartan, antihypertensive, poorly-soluble, BCS IV, solubility

1. Introduction

Azilsartan kamedoxomil is a prodrug quickly hydrolyzed to azilsartan, the active metabolite. It is employed as antihypertensive and can manage mild to moderate cases of essential hypertension [1,2].A solute's ability to mix evenly with a solvent is known as its solubility.A substance's solub ility is affected by temperature and pressure [3, 4]. The solvent could be a single chemical or a mixture of liquids [5]. Solubility should not be confused with the ability of a material to liquefy [6, 7].

Their poor bioavailability challenges the formulation of oral dosage forms. Many factors impact *bioavailability*, including solubility, permeability, dissolution, and first-pass metabolism, while *poor* bioavailability *is* referred to as low solubility and permeability. [8-9]. High doses of poorly soluble drugs are often needed to attain therapeutic plasma concentrations after ingestion. The low water solubility of new drugs and generic development is a significant obstacle in formulation. An aqueous solution is required for any drug to be absorbed. Most drugs exhibit weak acidity or basicity, resulting in limited water solubility. [10]

More than 40% of new drugs invented are practically insoluble in water. Consequently, the drug is absorbed slowly, which leads to poor bioavailability. For drugs taken orally, solubility is the most critical factor for determining the rate at which the desired strength in the bloodstream is achieved for a pharmacological response. [11]. Therefore, Improving the solubility and bioavailability of a drug is one of the biggest obstacles in formulation. There are different methods published in the literature to increase the solubility. The selected technique relied on various characteristics of the drug and the desired dosage form [12].

This review discusses in detail the several techniques that could help AZ, a candidate drug of BCS IV, enhance its solubility and bioavailability due to increased permeability.

2. Solubility enhancing technique

2.1.Nano suspension

A pharmaceutical nanosuspension comprises nanoparticles stabilized by several surfactants. This technique is employed for poorly soluble drugs. The particle size distribution in nanosuspensions ranges between 200 and 600 nm [13]. Nanosuspensions are the optimized technique in BCS class-

II and IV drug formulation since they result in high dissolution [14]. Another advantage of nanosuspension is that it can be easily manufactured [14].

Rajab and Jassem (2017) prepared and characterized AZ nanosuspension using different stabilizers such as polyethylene glycol 6000 (PEG 6000) with other co-stabilizers (Tween8). AZ nanosuspension exhibited rapid dispersibility and in-vitro dissolution [15].

2.2.Self-emulsifying drug delivery system (SMEDDS) and Nanoemulsion

SMEDDS is an anhydrous system of microemulsions that comprised of oil, surfactant and cosurfactant. Drug was dissolved in a mixture of surfactant and oil like oil-in-water microemulsions. SMEDDS revealed improve physical stability [16,17]. Madan et al developed AZ-SMEDDS for solubility enhancement of AZ containing Syloid® XDP 3150 had improved *in vitro* solubility when compared to pure AZ [18]

Nanoemulsion was designated a drug delivery system to enhance solubility and permeability, reduce adverse effects, elevate efficacy, and ease production and bioavailability [19, 20]. Several variables are critical in developing nanoemulsions and should be optimized [21]. These variables could be optimized by employing the central composite design (CCD) and the full-factorial design [22]. Kumar et al. (2022) developed an AZ nanoemulsion employing CCD to enhance its solubility and permeability using ethyl oleate, tween 80, and Transcutol P [23].

2.3. Solid dispersion

Solid dispersion makes the drug(s) dispersed in an carrier at a solid state designed by fusion methods [24]. Solid dispersion is the most commonly employed technique for enhancing the solubility of drugs. [25]. Many polymers are employed, such as polyvinylpyrrolidone and polyethylene glycol 4000 and 6000. Soluplus® with amphiphilic possessions that have dual character [26, 27]

This method uses an appropriate preparation technique to thoroughly distribute a medication in a water-soluble carrier. Particle size reduction typically speeds up the process of the drug changing from an amorphous to a crystalline state, which is a highly soluble, high-energy state; lately, the hydrophilic carrier has improved the drug particle's wettability. Solid medication dispersion aids in reducing drug particle size [28, 29].

Das et al developed AZ solid dispersions based on polyvinylpyrrolidone to enhance solubility. The investigation encompasses utilizing solvent evaporation and kneading techniques for solid dispersion preparation. Results indicate that solid dispersions produced through the solvent evaporation method exhibit superior enhancements in solubility compared to those prepared via kneading [30].

2.4. Liquisolid approach

The liquid solid technique could transform liquid or dissolved drugs into free-flowing, compressible powders. [31], in which the drug has a large surface area that permits the drug to dissolve freely and achieve excellent wettability [32, 33].

Water-miscible organic liquids like propylene glycol and polyethylene glycol 400, are employed. Sometimes, lipid-based liquid vehicles, like Captex, may increase the solubility of the drug when incorporated [34].

Chopra et al developed AZ liquisolid compacts that have been designed employing Capmul MCM and Captex as lipid vehicles; developed formulations were assessed for in vivo bioavailability, and the bioavailability of AZ was raised 1.29 times compared to pure AZ [34].

2.5. Complexation

Diverse complexation strategies employing cyclodextrins (CDs) have acquired good favor in recent years for increasing the solubilization of BCS II and IV. CDs are molecules with a hydrophilic exterior and lipophilic central cavity that locate lipophilic drugs that may enhance solubility and bioavailability by including complexes with drugs by putting the molecule into the cavity [35, 36]. CDs comprised (α-CD), (β-CD), or (γ-CD) units, having a hydrophilic hydroxyl group on their exterior surface and a hydrophobic hollow inside [37-39]. He et al. employed γ-CD metal-organic framework (CD-MOF) large molecular cages in which AZ was located, obtaining nanoclusters. AZ nanocluster solubility was raised 340-fold compared to the AZ [40].

2.6.Hydrotropy

Hydrotrophy is a solubilization approach where the expansion of the second solute, the hydrotropic operator, extends the fluid solvency of the first solute [41]. Adding substances or salts that expand dissolvability [42]. Ultrasonic may improve dissolvability due to complexation via the connection between the hydrotropic operators such as sodium benzoate, sodium acetic acid, sodium alginate, and urea and the drug [43-45]

Surwade et al. (2015) investigated AZ's solubility, which was determined separately in some hydrotropic operators at different concentrations, and the highest solubilization was obtained in a 40% sodium benzoate that included in urea: sodium acetate: sodium benzoate in 5:20:15 ratio that was utilized to prepare solid dispersions that released > 92% within 45 min [46].

2.7. Nonocrystals

Nanocrystals have sizes ranging from 10 to 1000 nm stabilized by stabilizers [47]. Nanocrystals are manufactured by many procedures, such as milling, high-pressure homogenization, and supercritical fluid technology; He et al. employed machine learning techniques to anticipate nanocrystals' particle size [48,49]. Per the Noyes–Whitney equation, nanocrystals with extensive surface areas could significantly enhance solubility [50,51]. Ma et al. improved the solubility and *in-vivo* bioavailability of AZ by the development of nanocrystals utilizing a bead milling method employing sodium deoxycholate with Poloxamer 188 [52].

3. Characterization

Fourier-transform infrared (FTIR) Spectrophotometric study employing product spectra were compared to the pure drug where peaks were observed [45]. AZ's powder X-ray diffraction PXRD and its characteristic peaks were investigated. Differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA) are employed to assess any complex formation or binding. Zeta potential is the case of microencapsulation. Finally, solubility and powder dissolution rate analysis were carried out [53].



Figure 1. illustrates and summarizes the methods and techniques of AZ solubility and characterization employed to ensure enhancing of solubility

List of Abbreviations

AZ: Azilsartan kamedoxomil

BCS: biopharmaceutical solubility class

CDs: cyclodextrins

PEG 6000: polyethylene glycol 6000

SMEDDS: Self-emulsifying drug delivery system

CCD: the central composite design

FTIR: Fourier-transform infrared

PXRD: powder X-ray diffraction PXRD

DSC: Differential scanning calorimetry

TGA: thermogravimetric analysis

Acknowledgments

I thank Al-Zahraa university for women for support

Conflict of Interest

The author declare no conflicts of interest

Funding

I depend on myself

Authors contributions

There is only one author

4. Conclusion

The review discussed many technologies that enable the dissolution of AZ. Moreover, they maximize drug dispersion, thereby improving oral bioavailability. Multiple investigations have revealed rapid dissolution and AZ absorption within formulations. One or more technologies could end the obstacles of low dissolution and absorption of AZ as a BCS IV candidate.

References

1. Pradhan A, Tiwari A, Sethi R. Azilsartan: Current Evidence and Perspectives in Management of Hypertension. International journal of hypertension. 2019; 1824621. https://doi.org/10.1155/2019/1824621.

2. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. International Scholarly Research Notices. 2012;2012.
3. Kumar A, Sahoo SK, Padhee K, Kochar PS, Sathapathy A, Pathak N. Review on solubility enhancement techniques for hydrophobic drugs. Pharmacie Globale. 2011;3(3):001-7. 3.
4. Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. International journal of pharmaceutical sciences review and research. 2010;5(1):41-51. 4.
5. Jain P, Goel A, Sharma S, Parmar M. Solubility enhancement techniques with special emphasis on hydrotrophy. International Journal of Pharma Professional's Research 2010 ;1(1):34-45.
6. Kale AR, Kakade S, Bhosale A. A Review on: Solubility Enhancement Techniques. Journal of Current Pharma Research. 2020;10(2):3630
7. Jagtap S, Magdum C, Jadge D, Jagtap R. Solubility enhancement technique: a review. Journal of pharmaceutical sciences and Research. 2018;10(9):2205-11.
8. Yellela SRK. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. Journal of Bioequivalence & Bioavailability. 2010;2(2):28–36.
9. Edward KH, Li D. Drug Like Properties: Concept, Structure, Design and Methods, from ADME to Toxicity Optimization. Elsevier; 2008. Solubility; p. p. 56.
10. Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. International Journal of Pharmaceutical Sciences Review and Research. 2010;5(1):41–51.
11. Sharma D, Soni M, Kumar S, Gupta GD. Solubility enhancement—eminent role in poorly soluble drugs. Research Journal of Pharmacy and Technology. 2009;2(2):220–224.
12. Kumar A, Sahoo SK, Padhee K, Kochar PS, Sathapathy A, Pathak N. Review on solubility enhancement techniques for hydrophobic drugs. *Pharmacie Globale.* 2011;3(3):001–007.

13. Priti M, Ruchira C, Ujwala D, Rohini C. Review: nanosuspension. Int J Pharm Sci Rev Res 2012; 13:118-24. 10. Kesisoglou F, Amitava M. Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds. AAPS J 2012; 14:677-87.
14. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen loaded acrylate polymer nanosuspensions for ophthalmic application. Biomater Sci 2002; 23:3247-55.
15. Ayash, N, Jassem, N. Design and in vitro evaluation of azilsartan medoxomil as self-dispersible dry nanosuspension. Journal of International Pharmaceutical Research, 2018; 45: 49-68. https://doi.org/10.13140/RG.2.2.22215.93606.
16. Deshmukh AS. Recent advances in self-emulsifying drug delivery system. International Journal of Pharmaceutical Sciences and Nanotechnology 2015; 8(1): 1-5.
17. Sriamornsak P, Limmatvapirat S, Piriyaprasarth S, Mansukmanee P and Huang Z. A New Self-Emulsifying Formulation of Mefenamic Acid with Enhanced Drug Dissolution. Asian Journal of Pharmaceutical Sciences 2015;10: 121-127.
18. Madan, J. R., Patil, K., Awasthi, R., & Dua, K. (2019). Formulation and evaluation of solid self-microemulsifying drug delivery system for azilsartan medoxomil. International Journal of Polymeric Materials and Polymeric Biomaterials2015; 70(2) :100–116. https://doi.org/10.1080/00914037.2019.1695206
19. McClements, D.J. Advances in Edible Nanoemulsions: Digestion, Bioavailability, and Potential Toxicity. Prog. Lipid Res. 2021; 81: 101081. https://doi.org/10.1016/j.plipres.2020.101081..

20. Kumar M, Bishnoi RS, Shukla AK, Jain CP. Techniques for Formulation of Nanoemulsion Drug Delivery System: A Review. *Prev. Nutr. Food Sci.* 2019; *24*: 225–234. https://doi.org/10.3746/pnf.2019.24.3.225.
21. Amarachinta PR, Sharma G, Samed N, Chettupalli AK, Alle M, Kim JC. Central Composite Design for the Development of Carvedilol-Loaded Transdermal Ethosomal Hydrogel for Extended and Enhanced Anti-Hypertensive Effect. J. Nanobiotech nol. 2021; 19: 100. https://doi.org/10.1186/s12951-021-00833-4.
22. Ngan CL, Basri M, Lye FF. Fard Masoumi HR, Tripathy M, Abedi Karjiban R, Abdul-Malek E. Comparison of Box– Behnken and Central Composite Designs in Optimization of Fullerene Loaded Palm-Based Nano-Emulsions for Cosmeceutical Application. *Ind. Crop. Prod.* 2014; *59*: 309–317. https://doi.org/10.1016/j.indcrop.2014.05.042
23. Kumar G, Virmani T, Pathak k, Al Kamaly O, Saleh A. Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation. Pharmaceuticals. 2022; 15: 1343. https://doi.org/10.3390/ph15111343.
24. Deshmukh DB, Gaikwad PD, Bankar VH, Pawar SP. Dissolution enhancement of poorly water soluble diacerein by solid dispersion technique. J Pharm Sci Res 2010; 2:734
25. Patil AN, Shinkar DM, Saudagar RB. Solubility enhancement by solid dispersion. I nt J Curr Pharm Res 2017; 9:15-8.
26. Shamma RN, Basha M. Soluplus®: a novel polymeric solubilizer for optimization of carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Tech 2013; 237:406-14.

27. Tamboli J, Mohite SK. Immediate release solid dispersion tablet of azilsartan: formulation strategy to enhance oral bioavailability. International Journal of Applied Pharmaceutics. 2020; 126-134. https://doi.org/10.22159/ijap.2020v12i4.37695.
28. Kumar S, Agrawal R. Solubility Enhancement of Poorly Water-Soluble Drugs by Solid Dispersion Techniques. International Journal of Pharma Professional's Research. 2023;14. 84-106. https://doi.org/10.48165/ijppronline.2023.14407.
29. Jadhav K, Hegaje S, Jadhav S, Vaidhya R, Redkar M. Formulation and Evaluation of Solid Dispersion of Poorly Soluble Drugs. Asian Journal of Pharmacy and Technology. 2022;12: 310-312. https://doi.org/10.52711/2231-5713.2022.00050.
30. Das, B, Patra A, Julekha K, Baldota J, Dutta, N, Malakar, M, Darshan V, Prasad S, Kumar A. Development and Characterization of Modified Dosage Forms of Azilsartan Medoxomil for Improved Solubility and Oral Bioavailability. African Journal of Biological Sciences. 2024; 6:1343-1353. https://doi.org/10.33472/AFJBS.6.9.2024.1342-1353.
31. Prajapat MD, Butani SB, Gohel MC. Liquisolid: a promising technique to improve dissolution efficiency and bioavailability of poorly water soluble nimodipine. J Drug Deliv Sci Technol 2019; 53:101135
32. Nnamani PO, Ugwu AA, Ibezim EC, et al. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance. Int J Nanomedicine 2016; 11:6365–6378
33. Nokhodchi A, Hentzschel CM, Leopold CS. Drug release from liquisolid systems: speed it up, slow it down. Expert Opin Drug Deliv 2011;8(02):191–205

34. Chopra D, Madhab D, Sahu P. Improvement of oral bioavailability of azilsartan medoxomil by lipid based liquisolid compacts: in vitro and in vivo evaluation. International Research Journal of Pharmacy. 2019; 9. 134-139. https://doi.org/10.7897/2230-8407.0912306.
35. Chowdary KPR, Srinivasan S. Effects of Cyclodextrins, Tween-80 and PVP on the Solubility and Dissolution Rate of Etoricoxib. J. Pharm. Sci. & Res 2011;3(7): 1344-1348.
36. Kumar S, Kasimedu S. Dissolution Enhancement of Poorly Soluble Drugs by Using Complexation Technique -A Review. Pharm. Sci. & Res. 2013; 5(5): 120 – 124
37. Noreen S, Maqbool I, Ijaz M, Tanveer S. Cyclodextrin Inclusion Complexes: Novel Techniques to Improve Solubility of Poorly Soluble Drugs: A Review. Global Pharmaceutical Sciences Review 2016; I: 29-34. https://doi.org/10.31703/gpsr.2016(I-I).04.
38. Rajabi O, Salari R, Tayyari S. Study of structure and properties of Lidocaine: hydroxypropyl-ß-cyclodxtrin inclusion complex, Journal of Pharmacy Research .2011; 4(5): 1562 1563.
39. Shivanand S. Influence of method of preparation on solubility, physicochemical properties and invitro release profile of simvastatin cyclodextrin inclusion complexes: A comparative study, International Journal of Current Pharmaceutical Research 2010; 2(2): 7-12.
40. He Y, Zhang W, Guo, T, Zhang G, Qin W, Zhang L et al. Drug nanoclusters formed in confined nano-cages of CD-MOF: dramatic enhancement of solubility and bioavailability of azilsartan. Acta Pharmaceutica Sinica B. 2018; 9. https://doi.org/10.1016/j.apsb.2018.09.003.

41. Maheshwari RK, Srivastav VK, Prajapat RP, Jain A, Kamaria P, Sahu S. New spectrophotometric estimation of ornidazole tablets employing urea as a hydrotropic solubilizing additive. Indian J Pharm Sci 2010; 72:258-61.
42. Maheshwari R, Rajput M, Sinha S. Ecofriendly spectrophotometric estimation of tinidazole in tablets using lignocaine HCL as a hydrotropic solubilising agent. Asian J Pharm 2009; 3:319-21.
43. Joshi J N, Nainwal S, Vikas A. A review on hydrotropy: a potential approach for the solubility enhancement of poorly soluble drug. Asian Journal of Pharmaceutical and Clinical Research. 2019; 19-26. https://doi.org/10.22159/ajpcr.2019.v12i10.34811.
44. Mahapatra, Abikesh & Patil, Vinod & Patil, Ravindra. Solubility Enhancement of Poorly soluble Drugs by using Novel Techniques: A Comprehensive Review. International Journal of PharmTech Research. 2020; 13: 80-93. https://doi.org/10.20902/IJPTR.2019.130211.
45. Bhamare V, Deore P, Katti S. Application of mixed hydrotropy for the solubility enhancement. World journal of pharmacy and pharmaceutical sciences. 2021; 10: 1163-1176. 10.17605/OSF.IO/XG9JU.
46. Surwade KS, Saudagar RB. Solubility enhancement of azilsartan medoxomil using mixed hydrotropy. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(7): 1167-79.
47. McGuckin MB, Wang JW, Ghanma R, Qin NY, Palma SD, Donnelly RF et al. Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes J Control Release 2022; 345: 334-353

48. He Y, Z.Ye Z, Liu XY, Wei ZG, Qiu F, Li HF, et al. Can machine learning predict drug nanocrystals?, J Control Release 2020; 322: 274-285

49. Xie B, Liu Y, Li X, Yang P, He W, Solubilization techniques used for poorly water-soluble drugs, Acta Pharmaceutica Sinica B, 2024,https://doi.org/10.1016/j.apsb.2024.08.027.

50. Tian ZH, Mai YP, Meng TT, Ma SJ, Gou GJ, Yang JH. Nanocrystals for improving oral bioavailability of drugs: intestinal transport mechanisms and influencing factors. AAPS PharmSciTech, 2021; 22: 179.

51. Meola TR, Dening TJ, Prestidge CA. Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone *in vitro*. Eur J Pharm Biopharm 2018; 129:145-153

52. Ma J, Yang Y, Sun Y, Sun J. Optimization, characterization and in vitro/vivo evaluation of azilsartan nanocrystals, Asian Journal of Pharmaceutical Sciences, 2017; 12 (4): 344-352. https://doi.org/10.1016/j.ajps.2016.09.008

53. Gao L, Zhang X. Synthesis of Two Novel Azilsartan Cocrystals: Preparation, Physicochemical Characterization and Solubility Studies. Crystals. 2020;10: 739. https://doi.org/10.3390/cryst10090739.